



Determinants of Influenza and Pertussis Vaccination Uptake in 
Pregnancy: A Multicenter Questionnaire Study of Pregnant 
Women and Healthcare Professionals
Wilcox, C.R., Calvert, A., Metz, J., Kilich, E., MacLeod, R., Beadon, 
K, Heath, P.T., Khalil, A., Finn, A., Snape, M.D., Vandrevala, T., 
Nadarzynski, T., Coleman, M.A. and Jones, C.E.
 
This is an accepted manuscript of an article published by Wolters Kluwer in The 
Pediatric Infectious Disease Journal, 38 (6), pp. 625-630.
The final definitive version is available online:
https://dx.doi.org/10.1097/INF.0000000000002242
© 2019 Wolters Kluwer
The WestminsterResearch online digital archive at the University of Westminster aims to make the 
research output of the University available to a wider audience. Copyright and Moral Rights remain 
with the authors and/or copyright owners.
Whilst further distribution of specific materials from within this archive is forbidden, you may freely 
distribute the URL of WestminsterResearch: ((http://westminsterresearch.wmin.ac.uk/).
In case of abuse or copyright appearing without permission e-mail repository@westminster.ac.uk
11 Attitudes of pregnant women and healthcare professionals 
2 towards clinical trials and routine implementation of 
3 antenatal vaccination against respiratory syncytial virus: a 
4 multi-centre questionnaire study
5
6
7 Christopher R Wilcox MBBCh 1, Anna Calvert MRCPH 2, Jane Metz MBBS 3, 
8 Eliz Kilich BM BCh 2, Rachael MacLeod MBChB 3, Kirsten Beadon BSc 4, 
9 Paul T Heath MRCPH 2, Asma Khalil MD 5,6, Adam Finn PhD 3, Matthew D 
10 Snape MD 4, Tushna Vandrevala PhD 7, Tom Nadarzynski PhD 8 9, Matthew A 
11 Coleman MD 10, Christine E Jones PhD 11
12
13
14 1: NIHR Clinical Research Facility, University Hospital Southampton 
15 NHS Foundation Trust, Southampton, UK
16
17 2: Vaccine Institute, St George's, University of London, London, UK
18
19 3: Bristol Children's Vaccine Centre, University of Bristol, Bristol, UK
20
21 4: Oxford Vaccine Group, Department of Paediatrics, University of 
22 Oxford and the NIHR Oxford Biomedical Research Centre, Oxford, 
23 UK
24
25 5: Fetal Medicine Unit, Department of Obstetrics and Gynaecology, 
26 St George's University Hospitals NHS Foundation Trust, London, UK
27
28 6: Vascular Biology Research Centre, Molecular and Clinical 
29 Sciences Research Institute, St George’s, University of London, 
30 London, UK
31
32 7: School of Social and Behavioural Sciences, Faculty of Business & 
33 Social Sciences, Kingston University, Kingston, London, UK
34
35 8: Department of Psychology, University of Southampton, 
36 Southampton, UK
37
38 9: Department of Psychology, University of Westminster, London, UK
39
40 10: Department of Fetal Medicine, Princess Anne Hospital, University 
41 Hospital Southampton NHS Foundation Trust, Southampton, UK
42
43 11: Faculty of Medicine and Institute for Life Sciences, University of 
44 Southampton and University Hospital Southampton NHS Foundation 
45 Trust, Southampton, UK
46
47 Abbreviated title
48 Attitudes to antenatal RSV vaccination: a questionnaire study
249
50 Running title
51 Attitudes to antenatal RSV vaccination
52
53 Corresponding author
54 - Dr Christopher Wilcox
55 - NIHR Clinical Research Facility, Southampton Centre for 
56 Biomedical Research, C Level West Wing, Mailpoint 218, 
57 Southampton General Hospital, Tremona Road, Southampton, 
58 SO16 6DY
59 - Email: christopher.wilcox@soton.ac.uk
60 - Telephone: 02381204956
61 - Fax: 02381205023
62
63 Keywords: Vaccination; Pregnancy; Respiratory Syncytial Virus; 
64 RSV; Clinical Trials; Attitudes
65
66 Conflict of Interests Statement
67 CW, AC, JM, KB, PH, AK, AF, MS and CJ are investigators for clinical 
68 trials done on behalf of their respective institutions, sponsored by 
69 various vaccine manufacturers, but receive no personal funding for 





76 Respiratory Syncytial Virus (RSV) is a common cause of infant 
77 hospitalisation and mortality. With multiple vaccines in 
78 development, we aimed to determine [1] the awareness of RSV 
79 amongst pregnant women and healthcare professionals (HCPs), and 
80 [2] attitudes towards clinical trials and routine implementation of 
81 antenatal RSV vaccination.
82
83 Methods
84 Separate questionnaires for pregnant women and HCPs were 




89 Responses from 314 pregnant women and 204 HCPs (18% 
90 obstetricians, 75% midwives, 7% unknown) were analyzed.  Most 
91 pregnant women (88%) and midwives (66%) had no/very little 
92 awareness of RSV, unlike obstetricians (14%).  Amongst pregnant 
93 women, 29% and 75% would likely accept RSV vaccination as part 
94 of a trial, or if routinely-recommended, respectively. Younger 
95 women (16-24 years), those of 21-30 weeks’ gestation, and with 
96 experience of RSV were significantly more likely to participate in 
97 trials (OR: 1.42 [1.72-9.86]; OR: 2.29 [1.22-4.31]; OR: 9.07 [1.62-
98 50.86], respectively). White-British women and those of 21-30 
99 weeks’ gestation were more likely to accept routinely-recommended 
100 vaccination (OR: 2.16 [1.07-4.13]; OR: 2.10 [1.07-4.13]). 
101 Obstetricians were more likely than midwives to support clinical 
102 trials (92% vs. 68%, OR: 2.50, 1.01-6.16) and routine RSV 
103 vaccination (89% vs. 79%, OR: 4.08, 1.53-9.81), as were those with 
104 prior knowledge of RSV, and who deemed it serious. 
105
4106 Conclusion
107 RSV awareness is low amongst pregnant women and midwives. 
108 Education will be required to support successful implementation of 
109 routine antenatal vaccination. Research is needed to understand 





116 Respiratory Syncytial Virus (RSV) is the leading viral cause of lower 
117 respiratory tract infection and bronchiolitis in infants, and is a major 
118 cause of hospitalization and mortality worldwide 1. RSV infects more 
119 that 60% of children in their first year of life, and almost 100% by 
120 two years of age 2. The estimated case fatality ratio for children 
121 hospitalized with severe RSV disease is 0.3% in industrialized 
122 countries, and 2.1% in developing countries3. Severe illness often 
123 occurs in children under six months 4, particularly in those born 
124 prematurely or with underlying chronic illness, and the development 
125 of novel prevention and treatment strategies is an international 
126 priority 5 6.
127
128 Antenatal vaccination is an effective means of protecting young 
129 infants from infection when the period of greatest susceptibility is 
130 shortly after birth 7–10 , and is now routinely recommended for use 
131 against a number of pathogens, including tetanus, influenza and 
132 pertussis 11. No vaccine against RSV is yet approved for routine use, 
133 however a number of candidates are in development 12 13, one of 
134 which is undergoing international phase III efficacy trials in pregnant 
135 women (NCT02624947)  11 14. An advantage of vaccination in 
136 pregnancy, rather than infancy, is that protection is afforded to 
137 infants from birth and extends through the period of highest risk of 
138 severe disease. 
6139
140 Achieving vaccine acceptance amongst pregnant women and 
141 maternity healthcare professionals (HCPs) has proven to be a 
142 considerable public health challenge, particularly in developed 
143 countries, and uptake of routine vaccination (especially influenza) 
144 remains suboptimal 15 . Furthermore, recruitment of pregnant 
145 women into clinical trials may be difficult, particularly as historically 
146 they have been excluded from participation, and there is a paucity 
147 of information regarding their recruitment and retention16 17. Pre-
148 emptively ascertaining the level of awareness of RSV amongst 
149 pregnant women and HCPs, as well as their attitudes to vaccine 
150 clinical trials and routine implementation of an RSV vaccine, may 
151 allow us to identify interventions to optimise both recruitment for 
152 future trials and uptake in a routine setting.
153
154 Our aims were to determine [1] the level of awareness of RSV 
155 amongst pregnant women and HCPs, and [2] their attitudes towards 















172 Questionnaire design and development
173 Two separate anonymized questionnaires were developed for 
174 pregnant women and maternity HCPs (see supplementary 
175 information). These were developed with input from a multi-
176 disciplinary study team including pediatricians, obstetricians, and 
177 health psychologists. Pregnant women and maternity HCPs were 
178 asked about their awareness and experience of RSV and 
179 bronchiolitis, pregnant women were asked whether they would 
180 hypothetically consider receiving an RSV vaccine as part of a clinical 
181 trial or if a vaccine were routinely recommended, and maternity 
182 HCPs if they would support clinical trials and routine 
183 recommendations. Women were also asked about the number of 
184 vaccines they would deem acceptable during pregnancy, and their 
185 opinions regarding the design of vaccine clinical trials. Part way 
186 through the questionnaire (having completed a self-assessment of 
187 their prior awareness/experience of RSV and bronchiolitis), 
188 participants were provided with written information on RSV and 
189 bronchiolitis inside a sealed envelope. This was done in order to 
190 inform further questions, whilst avoiding biasing their self-
191 assessment in the previous section. Ethical approval was granted 
192 (reference 17/LO/0537) and the study was registered on 
193 ClinicalTrials.gov prior to recruitment (NCT03096574).
194
9195 Study population and recruitment
196 The questionnaire for pregnant women was administered to women 
197 (aged > 16 years at the time of recruitment) attending for routine 
198 antenatal care at four study sites in southern England: University 
199 Hospital Southampton NHS Foundation Trust, Oxford University 
200 Hospitals NHS Foundation Trust, University Hospitals Bristol NHS 
201 Foundation Trust, and St George’s University Hospitals NHS 
202 Foundation Trust, London. These four study sites were selected due 
203 to their high birth rates (all >4000 births/year 18), and by 
204 distributing our questionnaire across four hospitals we attempted to 
205 increase the demographic diversity of our study population. The 
206 HCP questionnaire was administered to those working in either 
207 midwifery or obstetrics at the same four sites. Antenatal care for 
208 low-risk women in the UK is midwife-led, with women only seeing an 
209 obstetrician if they have a high-risk pregnancy, therefore the 
210 majority of potential respondents to our questionnaire were 
211 midwives. 
212
213 Recruitment of participants took place from July 2017 to January 
214 2018. Pregnant women were recruited in-person at antenatal clinics 
215 and wards by members of the study team on an opportunistic (non-
216 sequential) basis over the recruitment period, and given paper 
217 questionnaires to complete. For recruitment of HCPs, all 
218 obstetricians and midwives at the participating institutions were 
219 identified by a senior member of staff not involved in the study 
10
220 (using email distribution lists). They were then contacted via an 
221 email containing a link to an online questionnaire, followed by two 
222 email reminders. Alternatively, HCPs may also have been recruited 
223 in-person by the study team (in a similar fashion to pregnant 
224 women), in which case they were also given paper questionnaires. 
225 At the time of recruitment, information provided on the nature of 
226 the questionnaire was kept to a minimum in order to avoid biasing 
227 participant responses. The participant information sheet stated only 
228 that the aim of the study was to better understand their attitudes 
229 towards RSV and vaccination during pregnancy. Participation in the 
230 study was voluntary and no financial or other incentive was offered. 
231 All participants gave informed consent.
232
233 Questionnaire data analysis
234 Questionnaire data were entered at the lead site (Southampton) into 
235 iSurvey (www.isurvey.soton.ac.uk). Statistical analysis was 
236 performed using IBM SPSS Statistics version 25. Ordinal regression 
237 analysis was performed, and adjusted odds ratios (ORs) and 95% 
238 confidence intervals (CI) were calculated. P-values <0.05 were 
239 considered as statistically significant. Multicollinearity was 
240 examined using the tolerance test and the Variance Inflation Factor 
241 (VIF) to ensure variables with a VIF value exceeding 2.5 were not 








249 A total of 525 participants completed the questionnaires: 321 
250 pregnant women and 204 HCPs (18% obstetricians, 75% midwives, 
251 and for 7% the professional role was unknown). Seven 
252 questionnaires from pregnant women, and five from HCPs, were 
253 excluded due to largely incomplete or illegible responses, leaving 
254 513 (98%) for analysis. The numbers of respondents were equally 
255 distributed between the four study sites. The full characteristics of 
256 respondents are displayed in Table 1. 
257
258 Responses from pregnant women 
259 Most pregnant women reported no (71%) or very little (17%) 
260 awareness of RSV, and reported no experience (93%) [see Figure 1]. 
261 They were much more familiar with the term ‘bronchiolitis’ (only 
262 14% had never heard of it), and bronchiolitis tended to be perceived 
263 as more common and serious than RSV. 
264
265 Of 312 who responded, 28% were likely/very likely, 32% not sure, 
266 and 40% unlikely/very unlikely to consider receiving RSV 
267 vaccination as part of a clinical trial. The most important information 
268 to women was the likelihood of side effects for their baby (see 
269 Figure 2). Ordinal regression analysis (see Table 2) demonstrated 
270 that women were significantly more likely to accept RSV vaccination 
13
271 as part of a clinical trial if they had direct experience of RSV (OR: 
272 9.07, 95% CI: 1.62-50.86), were of younger age (16-24 years, OR: 
273 1.42, 95% CI: 1.72-9.86) and of 21-30 weeks’ gestation (OR: 2.29, 
274 95% CI: 1.22-4.31). Women were significantly less likely to consider 
275 taking part if they perceived bronchiolitis as extremely/moderately 
276 serious (OR: 0.38, 95% CI: 0.15-0.93) or somewhat serious (OR: 
277 0.27, 95% CI: 0.11-0.68). 
278
279 More women would accept the vaccine if it was routinely 
280 recommended: of 308 who responded, 40% were very likely, 35% 
281 likely, 16% not sure, 5% unlikely and 4% very unlikely. Women were 
282 significantly more likely to accept routine RSV vaccination if they 
283 identified as White British (OR: 2.16, 95% CI: 1.22-3.83) versus non-
284 White British, and were of 21-30 weeks’ gestation (OR: 2.10, 95% 
285 CI: 1.07-4.13)
286
287 The most popular method of being approached regarding study 
288 involvement was face-to-face by their midwife (37%), but 26% 
289 wouldn’t have a preference (see Figure 3). The amount of time 
290 pregnant women would need to consider whether or not to 
291 participate in a trial was variable, but 72% responded < one week 
292 (17% <24 hours, 22% 1-2 days, 33% 3-7 days, 18% 2-3 weeks, and 
293 10% >1 month). For the majority (82%), their decision to participate 
294 wouldn’t be altered if the study was a randomised controlled trial, 
295 but 15% would be less likely to take part, and 3% would be more 
14
296 likely. For 66%, their decision wouldn’t be altered if the study 
297 involved different doses of vaccine, but 31% would be less likely to 
298 take part, and 3% would be more likely. The number of vaccines in 
299 pregnancy deemed acceptable by women was variable, however 
300 25% would accept two vaccines or less, 27% would accept three, 
301 11% four, 6% five, and 32% would accept more than five (i.e. as 
302 many as were recommended). Finally, in the free-text comments 
303 (see supplementary information), some women raised concerns 
304 regarding side-effects for their baby, and others stated support for 
305 vaccination, often describing personal experience. 
306
307 Responses from maternity healthcare professionals
308 HCPs had greater awareness and experience of RSV than pregnant 
309 women, however obstetricians were significantly more familiar than 
310 midwives with both RSV (OR: 9.42, 95% CI: 5.08-25.30, p<0.0001) 
311 and bronchiolitis (OR 2.68, 95% CI: 1.29-5.55, p=0.008) [see Figure 
312 1].
313
314 Of 192 HCPs who responded, 72% were likely/very likely, 19% not 
315 sure, and 9% unlikely/very unlikely to support a clinical trial of RSV 
316 vaccination. The most important information to HCPs was the 
317 likelihood of side effects for the baby.  Ordinal regression analysis 
318 (see Table 2) demonstrated that HCPs were significantly more likely 
319 to consider supporting a clinical trial if they were obstetricians (OR: 
320 2.50, 95% CI: 1.01-6.16), had good/some understanding of RSV (OR: 
15
321 4.42, 95% CI: 1.10-17.83), and perceived RSV as extremely (OR: 
322 4.85, 95% CI: 1.11-21.28) or moderately/somewhat serious (OR: 
323 4.16, 95% CI :1.26-13.75). Likelihood of support also varied between 
324 study sites, with HCPs from sites A, B and C being significantly more 
325 likely to support a trial than those in site D. 
326
327 More HCPs would support administration of the vaccine if it was 
328 routinely recommended: 47% definitely, 34% likely, 14% not sure, 
329 4% unlikely and 0.5% very unlikely. Obstetricians were significantly 
330 more likely than midwives to support the administration of a routine 
331 RSV vaccine (OR: 4.08, 95% CI: 1.53-9.81), as were those HCPs with 
332 good/some understanding of RSV (OR: 6.07, 95% CI: 1.23-29.93) 
333 and those who perceived RSV as moderately/somewhat serious (OR: 
334 4.41, 95% CI: 1.32-14.78) [see Table 3]. Likelihood of supporting a 
335 routine RSV vaccine also varied significantly by study site with HCPs 
336 from sites A, B being significantly more likely to support routine 
337 vaccination than those in site D. Finally, in the free-text comments 
338 [see supplementary information] some HCPs reported concerns 











349 The high burden of RSV infection has driven recent efforts to 
350 develop an effective antenatal vaccine. This is a large multi-centre 
351 study in which we have attempted to establish the level of 
352 awareness of RSV, and attitudes to vaccine clinical trials and routine 
353 implementation of an RSV vaccine during pregnancy. 
354
355 The awareness of RSV was low amongst pregnant women and 
356 midwives, compared with obstetricians. Younger pregnant women, 
357 those of 21-30 weeks’ gestation, and those recalling direct 
358 experience of RSV, were significantly more likely to consider 
359 involvement in an RSV vaccine trial; and direct face-to-face 
360 interaction with a midwife was the preferred method of potential 
361 recruitment (amongst those who had a preference). Encouragingly, 
362 the majority of women would accept routine RSV vaccination, yet 
363 some (25%) would still be unsure or unlikely to accept vaccination, 
364 particularly those of ethnic minorities, and one-quarter would accept 
365 < 2 vaccines during pregnancy. Approximately 70% and 80% of 
366 HCPs would be likely to support an RSV vaccine trial and routine 
367 RSV vaccination respectively. Obstetricians were more likely than 
368 midwives to support both RSV trials and routine vaccination, as 
369 were those with prior knowledge of RSV and those who perceived it 
370 as a serious cause of infection. Support for potential RSV trials and 
371 routine vaccination also varied significantly by study site. 
18
372
373 It is notable that the awareness of RSV is so low given that RSV-
374 associated respiratory tract infection is one of the commonest 
375 causes of infant hospitalisation and mortality worldwide 1. Being 
376 thoroughly informed as to the indication and efficacy of vaccination 
377 has been shown to significantly increase the probability of its 
378 acceptance19 20. Therefore, with a number of RSV vaccine 
379 candidates currently in development, further education of both 
380 pregnant women and HCPs will be needed if we are to optimise 
381 engagement with vaccination trials and eventual uptake of RSV 
382 vaccines as part of routine care. Both pregnant women and HCPs 
383 seemed to better identify with the term bronchiolitis than RSV, and 
384 therefore specifically highlighting the link between these may be 
385 helpful in educational strategies. We do note that those who 
386 perceived bronchiolitis as serious were significantly less likely to 
387 consider participating in an RSV trial, however it is possible that this 
388 is a result of confounding due to a lack of knowledge regarding 
389 bronchiolitis. It is also interesting to note that women of 21-30 
390 weeks’ gestation were significantly more accepting of both RSV 
391 trials and routine vaccination, perhaps due to a sense of 
392 reassurance following their 20-week anomaly scan and subsequent 
393 clinical review. Finally, the finding that women of ethnic minorities 
394 were less likely to accept routine RSV vaccination has been similarly 
395 observed in a number of previous studies of routinely-recommended 
396 vaccines21–23, yet the underlying reasons remain poorly understood, 
19
397 and may include cultural/religious differences, as well as language 
398 barriers.
399
400 It is concerning that a number of the HCPs surveyed in this study 
401 would be unlikely to support either clinical trials or routine 
402 vaccination against RSV. Maternity HCPs can be strong advocates 
403 for antenatal vaccination, and encouragement from them 
404 (particularly midwives) may increase intention by up to 20 times2425. 
405 Furthermore, HCPs are well-placed to facilitate clinical trial 
406 recruitment by identifying and speaking directly to eligible women, 
407 and addressing specific concerns about research safety and 
408 practicality17. It is important to note that obstetricians were 
409 significantly more willing to provide support for both clinical trials 
410 and routine vaccination than midwives, independent of their prior 
411 knowledge/experience of RSV or bronchiolitis. Barriers to 
412 engagement of midwives and nurses in research that have been 
413 identified in previous studies, include high workload, insufficient 
414 staff numbers and resources, a lack of confidence, and a lack of a 
415 research-supportive culture 26 27. Finally, the observed differences in 
416 support for both routine vaccination and clinical trials between 
417 study sites also suggests that there may be a potential risk of health 
418 inequalities based on differing recommendations across the South of 
419 England. All four sites had been involved in trials of antenatal 
420 vaccination (including RSV trials) prior to this study, and all have 
421 recently embedded vaccination into their routine antenatal care 
20
422 service. Site D only recently set up this vaccination service however 
423 (following the completion of this study), whereas it has been 
424 operating at the other sites for a longer period of time. They also 
425 report having comparatively less involvement from clinical teams in 
426 their vaccination trials. This may therefore, at least in part, explain 
427 the lower acceptance at this institution compared with sites A, B and 
428 C.
429
430 Implications for clinical practice and research
431 It is clear that education about RSV and bronchiolitis for pregnant 
432 women will be required in order to optimise uptake rates of 
433 antenatal RSV vaccination if it is introduced into routine care. Such 
434 education should highlight the safety and benefits of vaccination for 
435 their child, as studies have consistently shown that perception of 
436 potential harm to the baby is the primary reason for vaccine refusal 
437 25 28, whereas messages emphasising the protective benefits 
438 conferred to infants is a major motivator for pregnant women to 
439 undergo vaccination 29. As well as face-to-face counselling, possible 
440 strategies could include paper and online education resources 40  30, 
441 as well as mobile phone text messages (such as Text4baby 31) and 
442 smart phone apps (such as MatImms 32). Education for HCPs on RSV 
443 and bronchiolitis will also be required in order to ensure active 
444 promotion of vaccination, and individual institutions should aim to 
445 tackle any general vaccine hesitancy within their own working body.
446
21
447 With regards to improving uptake into future antenatal vaccine 
448 trials, it is important to note that the majority of our respondents 
449 wouldn’t be deterred by a randomized controlled trial design, and 
450 that direct face-to-face interaction with an HCP was the preferred 
451 method of recruitment. Improving study team outreach and forming 
452 integrated networks between research teams and healthcare 
453 providers/clinical staff may help improve clinicians’ willingness to 
454 promote clinical studies to their patients, as well as pregnant 
455 women's willingness to join studies 17, and this has proven a 
456 successful method of recruiting pregnant women in previous studies 
457 33 34. Social media and web-based recruitment may be used as a 
458 cost-effective supplement to traditional recruitment methods, and 
459 facilitate participation of traditionally harder-to-reach populations 17 
460 35, however this approach may be less successful for higher-risk 
461 intervention-based studies, including antenatal vaccine trials.
462
463 Finally, it should be noted that there are other potential antenatal 
464 vaccines in development (including group B streptococcus and 
465 cytomegalovirus 11), for which education and support from staff will 
466 also be required for successful implementation 22 . Furthermore, it is 
467 also worth considering that whilst a third of our respondents would 
468 accept as many vaccines as were recommended, many women may 
469 be reluctant to accept high numbers of vaccines, especially if given 
470 on separate occasions36 37. Pragmatic research is therefore required 
22
471 to consider the logistical aspects of future antenatal vaccine 
472 delivery. 
473
474 Strengths and limitations 
475 This study had significant numbers of respondents, and by 
476 distributing our questionnaire across four hospitals in southern 
477 England we attempted to maximise the diversity of our study 
478 population. That said, the responses to the questionnaire cannot be 
479 taken as representative of all pregnant women and maternity HCPs. 
480 Our respondents were all recruited from antenatal clinics based in 
481 tertiary hospitals, and therefore it is also possible that our sample 
482 was missing subsets of the population that tend to be more anti-
483 vaccination. Future studies might benefit from recruiting over a 
484 wider geographical area, and from different types of sites (such as 
485 non-tertiary hospitals and primary care), and perhaps utilising 
486 online recruitment via pregnancy-associated websites and social 
487 media. It may have been also beneficial to collect socio-economic 
488 data from our participants in order to assess the representativeness 
489 of our study sample. Other limitations are that data on the uptake of 
490 antenatal vaccination was not collected from women’s medical 
491 records following delivery, and data on the uptake of influenza 
492 vaccination amongst HCPs wasn’t collected. Finally, the number of 
493 pregnant women/HCPs approached, and the number who declined 
494 participation (as well as their reasons for doing so) was not 




498 RSV awareness appears low amongst pregnant women and 
499 midwives in the UK. Education will be required to optimise 
500 engagement with vaccination trials and eventual uptake of RSV 
501 vaccination following routine implementation, with an emphasis on 
502 women of ethnic minorities. Active promotion of vaccination must 
503 be incorporated into routine antenatal care, and further research is 
504 needed to understand reasons for vaccine hesitancy amongst both 





510 Figure captions [images to be reproduced in colour 
511 online only]:
512
513 Figure 1: Reported familiarity and experience with RSV (A & B) and 
514 bronchiolitis (C) amongst pregnant women, midwives and 
515 obstetricians, prior to their involvement in this study.
516
517 Figure 2: Information that would be considered most important to 
518 the pregnant women in this study when deciding whether to take 
519 part in a research study of an RSV vaccine (A), and other factors 
520 which would discourage them from taking part (B).
521
522 Figure 3: Preferred method of being approached regarding 
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697 Table 1: Characteristics of the questionnaire respondents (pregnant women and 









     16-24 34 (11%)
     25-30 107 (34%)
     31-35 92 (29%)
     36-40 58 (19%)
     41+ 13 (4%)
Gestation (weeks)
     <12 8 (2%)
     12-16 37 (12%)
     17-20 31 (10%)
     21-30 55 (18%)
     31-36 93 (30%)
     >37 76 (24%)
Study site
     A 88 (28%) 43 (22%)
     B 77 (25%) 53 (27%)
     C 79 (25%) 61 (31%)
     D 70 (22%) 42 (21%)
Ethnicity
     Asian (British, Indian, Pakistani, Bangladeshi, 
Chinese, other)
25 (8%) 4 (2%)
     Black (British, African, Caribbean, other) 17 (5%) 4 (2%)
     White (British, Irish, other) 248 (79%) 175 (88%)
     Mixed (Caribbean, African, Asian, other) 11 (4%) 6 (3%)
     Other ethnic group (Arab, other) 3 (1%) 0 (0%)
     Did not want to say 1 (0.3%) 1 (1%)
     No response 10 (3%) 9 (5%)
Has children
    No 142 (45%) 72 (36%)
    Yes 172 (55%) 127 (64%)
Profession
     Obstetrics 37 (19%)
     Midwifery 151 (76%)
     No response 11 (6%)
Midwifery seniority
     Band 5 (newly-qualified midwife) 8 (5%)
     Band 6 (junior midwife) 84 (56%)
     Band 7 (senior midwife) 46 (30%)
     Band 8 (midwifery manager) 8 (5%)
      No response 5 (3%)
Obstetrician seniority
     Specialty training years 1-3 (or equivalent) 8 (22%)
     Specialty training years 4-6 (or equivalent) 6 (16%)
     Specialty training years 7-8 (or equivalent) 6 (16%)
     Consultant 17 (46%)
Time spent working in maternity care (years)
     <2 17 (9%)
     2-5 29 (15%)
     6-10 37 (19%)
     11-15 20 (10%)
     16-20 26 (13%)
     >21 62 (31%)
     No response 8 (4%)
30
703 Table 2: Ordinal regression analysis of factors predicting pregnant women’s willingness to 




Variable Number who’d be 
‘extremely likely’ or 
‘likely’ to accept RSV 
vaccination as part of 
a clinical trial
Adjusted odds ratio 
(95% CI)
Number who’d be 
extremely likely’ or 
‘likely’ to accept RSV 





16-24 18/34 (53%) 1.42 (1.72-9.86) ** 27/34 (79%) 0.68 (0.28-1.67)
25-35 54/199 (27%) 1.18 (0.67-2.07) 149/198 (75%) 0.71 (0.39-1.28)
36-45 16/70 (23%) 1.00 for reference 53/70 (76%) 1.00 for reference
Gestation in weeks
<12 3/8 (38%) 1.99 (0.46-8.51) 6/8 (75%) 0.67 (0.15-3.00)
12-20 24/68 (35%) 1.26 (0.72-2.22) 52/68 (76%) 1.17 (0.65-2.10)
21-30 18/55 (33%) 2.29 (1.22-4.31) ** 42/54 (78%) 2.10 (1.07-4.13) *
31+ 43/168 (26%) 1.00 for reference 128/168 (76%) 1.00 for reference
Study site
Site A 25/86 (29%) 0.80 (0.40-1.59) 65/87 (75%) 0.99 (0.49-2.00)
Site B 23/77 (30%) 0.72 (0.35-1.49) 62/76 (82%) 1.26 (0.59-2.69)
Site C 20/79 (25%) 0.54 (0.26-1.10) 55/76 (72%) 0.78 (0.37-1.63)
Site D 20/70 (29%) 1.00 for reference 50/69 (72%) 1.00 for reference
Previous children
Yes 50/171 (29%) 1.13 (0.71-1.81) 122/171 (71%) 0.64 (0.39-1.05)
No 39/141 (28%) 1.00 for reference 110/137 (80%) 1.00 for reference
Ethnicity
White British 66/224 (29%) 1.27 (0.73-2.21) 177/223 (79%) 2.16 (1.22-3.83) **
Non-White British 23/88 (26%) 1.00 for reference 55/85 (65%) 1.00 for reference
Previous RSV experience
Direct experience 5/8 (63%) 9.07 (1.62-50.86) * 8/8 (100%) 8.20 (0.71-94.16)
Indirect experience 5/13 (38%) 1.11 (0.32-3.81) 10/13 (77%) 1.09 (0.30-3.96)
No experience 79/291 (27%) 1.00 for reference 214/287 (75%) 1.00 for reference
RSV familiarity
Good/some understanding 5/14 (36%) 0.54 (0.12-2.30) 11/14 (79%) 1.77 (0.37-8.56)
Poor understanding 21/77 (27%) 0.80 (0.47-1.38) 55/76 (72%) 0.96 (0.55-1.68)
No understanding 63/219 (29%) 1.00 for reference 164/216 (76%) 1.00 for reference
Perceived RSV frequency
Extremely/moderately common 18/50 (36%) 1.12 (0.53-2.35) 39/51 (76%) 1.03 (0.47-2.23)
Somewhat common 34/99 (34%) 1.52 (0.88-2.61) 75/98 (77%) 0.93 (0.53-1.64)
Slightly/not at all common 37/143 (26%) 1.00 for reference 107/141 (76%) 1.00 for reference
Perceived RSV severity
Extremely/moderately serious 43/129 (33%) 1.22 (0.58-2.57) 100/129 (78%) 1.31 (0.60-2.86)
Somewhat serious 33/117 (28%) 0.93 (0.47-1.84) 87/115 (76%) 1.06 (0.52-2.18)
Slightly/not at all serious 13/43 (30%) 1.00 for reference 33/43 (77%) 1.00 for reference
Bronchiolitis familiarity and experience
Good/moderate understanding and 
direct/indirect experience 
27/88 (31%) 1.30 (0.65-2.60) 68/89 (76%) 0.75 (0.36-1.53)
Slight understanding 29/102 (28%) 1.13 (0.63-2.00) 77/101 (76%) 0.81 (0.44-1.48)
No understanding 32/120 (27%) 1.00 for reference 86/116 (74%) 1.00 for reference
Perceived bronchiolitis frequency
Extremely/moderately common 33/107 (31%) 0.67 (0.33-1.37) 85/107 (79%) 1.04 (0.49-2.19)
Somewhat common 26/96 (27%) 1.25 (0.68-2.31) 69/95 (73%) 1.36 (0.72-2.60)
Slightly/not at all common 26/101 (26%) 1.00 for reference 73/98 (74%) 1.00 for reference
Perceived bronchiolitis severity
Extremely/moderately serious 55/190 (29%) 0.38 (0.15-0.93) * 143/188 (76%) 0.63 (0.24-1.65)
Somewhat serious 19/84 (23%) 0.27 (0.11-0.68) * 62/84 (74%) 0.52 (0.20-1.36)
Slightly/not at all serious 11/28 (39%) 1.00 for reference 20/26 (77%) 1.00 for reference
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709 Table 3: Ordinal regression analysis of factors predicting the willingness of healthcare 
710 professionals to support RSV vaccination during pregnancy as part of a clinical trial, or if 
711 routinely recommended
Variable Number who’d 
be ‘very likely’ 
or ‘likely’ to 
support RSV 
vaccination as 





be ‘very likely’ 








Obstetrics 34/37 (92%) 2.50 (1.01-6.16) * 33/37 (89%) 4.08 (1.53-9.81) 
**
Midwifery 102/151 (68%) 1.00 for reference 119/151 (79%) 1.00 for 
reference
Time in maternity care
21+ years 46/62 (74%) 0.51 (0.14-1.83) 46/62 (74%) 0.43 (0.12-1.62)
11-20 years 31/46 (67%) 0.38 (0.11-1.34) 34/46 (74%) 0.79 (0.22-2.86)
2-10 years 47/66 (71%) 0.68 (0.22-2.10) 60/66 (91%) 1.39 (0.43-4.42)
<2 years 14/17 (82%) 1.00 for reference 15/17 (88%) 1.00 for 
reference
Study site
Site A 30/41 (73%) 3.94 (1.46-10.61) 
**
34/41 (83%) 3.95 (1.39-11.26) 
*
Site B 35/53 (66%) 3.19 (1.23-8.30) * 46/53 (87%) 6.23 (2.22-17.46) 
***
Site C 51/61 (84%) 5.80 (2.36-14.21) 
***
47/61 (77%) 1.97 (0.81-4.83)
Site D 22/37 (59%) 1.00 for reference 29/37 (78%) 1.00 for 
reference
Has own children
Yes 88/127 (69%) 0.59 (0.28-1.24) 101/127 (80%) 0.86 (0.39-1.91)
No 50/65 (77%) 1.00 for reference 55/65 (85%) 1.00 for 
reference
Ethnicity
White British 126/175 (72%) 1.01 (0.34-3.06) 142/175 (81%) 1.41 (0.44-4.46)
Non-White British 12/17 (71%) 1.00 for reference 14/17 (82%) 1.00 for 
reference
RSV experience
Direct experience 22/26 (85%) 2.65 (0.79-8.86) 24/26 (92%) 1.41 (0.39-5.07)
Indirect experience 20/27 (74%) 1.17 (0.42-3.31) 23/27 (85%) 0.74 (0.25-2.22)
No experience 96/139 (69%) 1.00 for reference 109/139 (78%) 1.00 for 
reference
RSV familiarity
Good/some understanding 19/22 (86%) 4.42 (1.10-17.83) 
*
20/22 (91%) 6.07 (1.23-29.93) 
*
Poor understanding 87/114 (76%) 1.81 (0.88-3.73) 91/114 (80%) 1.07 (0.51-2.24)
No understanding 32/55 (58%) 1.00 for reference 44/55 (80%) 1.00 for 
reference
Perceived RSV frequency
Extremely common 29/36 (81%) 1.43 (0.45-4.51) 30/36 (83%) 1.96 (0.57-6.76)
Moderately/somewhat common 84/116 (72%) 0.92 (0.43-1.98) 95/116 (82%) 1.20 (0.54-2.67)
Slightly/not at all common 25/39 (64%) 1.00 for reference 30/39 (77%) 1.00 for 
reference
Perceived RSV severity
Extremely serious 27/35 (77%) 4.85 (1.11-21.28) 
*
26/35 (74%) 1.25 (0.28-5.55)
Moderately/somewhat serious 113/138 (82%) 4.16 (1.26-13.75) 
*
117/138 (85%) 4.41 (1.32-14.78) 
*
Slightly/not at all serious 8/17 (47%) 1.00 for reference 12/17 (71%) 1.00 for 
reference
Bronchiolitis familiarity and 
experience
Good/moderate understanding 
and indirect/direct experience 
58/77 (75%) 0.84 (0.10-6.94) 66/77 (86%) 0.99 (0.12-8.35)
Slight understanding 78/111 (70%) 0.98 (0.13-7.49) 87/111 (78%) 0.98 (0.13-7.56)




Extremely common 29/34 (85%) 1.05 (0.34-3.25) 27/34 (79%) 0.55 (0.17-1.80)
Moderately/somewhat common 88/124 (71%) 1.44 (0.63-3.29) 104/124 (84%) 1.07 (0.45-2.51)








Extremely serious 36/47 (77%) 0.35 (0.054-2.28) 38/47 (81%) 0.96 (0.15-6.39)
Moderately/somewhat serious 96/136 (71%) 0.29 (0.052-1.65) 111/136 (82%) 0.54 (0.10-2.99)






719 1) Questions for pregnant women analysed in this study
720
721 (1) Before taking part in this survey, how familiar were you with Respiratory Syncytial Virus 
722 (sometimes shortened to RSV)?
723 ☐ I have never heard of it
724 ☐ I have heard of it, but don’t really know what it is
725 ☐ I know some facts about what it is 
726 ☐ I have a good understanding about RSV infection and its implications 
727
728 (2) What experience do you have of RSV?
729 ☐ I have no experience of it
730 ☐ I know someone who has experience of it
731 ☐ I have direct experience of it 
732
733 (3) How common do you think RSV infection is in babies and young children?
734 ☐ Not at all common
735 ☐ Slightly common
736 ☐ Somewhat common
737 ☐ Moderately common
738 ☐ Extremely common
739
740 (4) How serious do you think RSV infection is for babies and young children?
741 ☐ Not at all serious
742 ☐ Slightly serious
743 ☐ Somewhat serious
744 ☐ Moderately serious
745 ☐ Extremely serious
746      
747 (5) Before taking part in this survey, how familiar were you with bronchiolitis in babies and 
748 young children?
749 ☐ I have never heard of it
750 ☐ I have heard of it but don’t know what it is
751 ☐ I know some facts about it
752 ☐ I know what it is and know someone who has experience of it
753 ☐ I know what it is and have direct experience of it 
754
755 (6) How common do you think bronchiolitis is in babies and young children?
756 ☐ Not at all common
757 ☐ Slightly common
758 ☐ Somewhat common
759 ☐ Moderately common
760 ☐ Extremely common
761
762
763 (7) How serious do you think bronchiolitis is for babies and young children?
764 ☐ Not at all serious
765 ☐ Slightly serious
766 ☐ Somewhat serious
767 ☐ Moderately serious
768 ☐ Extremely serious
769
770 (8) Would you be potentially willing to receive a RSV vaccine during pregnancy as part of a 
771 research study to determine its safety and effectiveness, before the vaccine is approved for 
772 routine use?  
34
773
774 Your response to this question will not affect whether or not you receive further information about such 
775 studies and does not mean that you are agreeing to take part in any vaccine research studies. 
776
777 ☐ Extremely unlikely
778 ☐ Unlikely
779 ☐ Neutral/not sure
780 ☐ Likely
781 ☐ Extremely likely  
782
783 (9) What information would you consider to be important when considering taking part in a 
784 research study of a RSV vaccine? 
785
786 Please rank the top 3 most important to you: (1= most important information for you to know)
787
788 ☐ How common RSV is
789 ☐ How serious RSV is
790 ☐ Number of healthy adults who have received the vaccine
791 ☐ Number of pregnant women who have received the vaccine
792 ☐ Likelihood of side effects for me
793 ☐ Likelihood of side effects for my baby
794
795 (10) One type of a research study is a “Randomised Controlled Trial” where there are two (or 
796 more) groups who are treated exactly the same, except only one group gets the true vaccine 
797 under investigation. The other group may get a ‘placebo’ (dummy or inactive) injection. 
798
799 This type of study allows the researchers to check that any differences between the groups are 
800 due to the vaccine only. Importantly, patients or staff do not get to choose whether they receive 
801 the proper vaccine or the dummy.
802
803 After reading the above information:
804 ☐ I would be less likely to take part as I would want to guarantee that I would have the vaccine 
805 ☐ I would be more likely to take part as I might not get the vaccine 
806 ☐ This would not affect my decision
807
808
809 (11) In some randomised controlled trials, patients are given different doses (amounts) of the 
810 vaccine under investigation in order to work out which is the best dose to use in future vaccines. 
811 These different doses would be calculated before the trial starts, but patients or staff involved in 
812 the study do not get to choose which of these doses they receive.
813 After reading the above information:
814 ☐ I would be less likely to take part 
815 ☐ I would be more likely to take part
816 ☐ This would not affect my decision
817
818 (12) What other factors would discourage you from taking part in a research study of a vaccine 
819 in pregnancy?
820 Please rank the following: (1= factor that would most discourage you, 4= factor least likely to 
821 discourage you)
822 ☐ Number of hospital visits
823 ☐ Number of home visits
824 ☐ Number of blood tests for me
825 ☐ Number of blood tests for baby




830 (13) How would you most like to be approached about taking part in a research study?
831 Tick one answer:
832 ☐ Asked by my midwife
35
833 ☐ Asked by my obstetrician 
834 ☐ Asked by my GP
835 ☐ Given a leaflet/poster with contact details for the study team
836 ☐ Adverts of the internet (e.g. pregnancy forums)
837 ☐ Email from the study team 
838 ☐ Approached directly by the study midwife/doctor





844 (14) If you were approached about taking part in a research study, how much time would you 
845 like to fully consider whether or not you would like to take part?
846 ☐ <24 hours
847 ☐ 1-2 days
848 ☐ 3-7 days
849 ☐ 2-3 weeks
850 ☐ >1 month
851
852 (15) Would you be willing to receive this vaccine in pregnancy if it was routinely recommended 




857 ☐ Probably not
858 ☐ Definitely not
859
860 (16) There are a number of different vaccines that are being designed for use in pregnancy to 
861 protect mothers and infants against severe infection. How many vaccines would be acceptable to 







869 ☐ More than 5
870
871 (27) How old are you in years?
872 16-24 ☐ 25-30 ☐ 31-35 ☐ 36-40 ☐ 41-45 ☐  46+ ☐ 
873  
874 (28) How many weeks pregnant are you?
875 Less than 12 ☐ 12-16 ☐ 17-20 ☐ 21-30 ☐ 31-36 ☐ 37+ ☐ 
876
877 (19) To what ethnic group do you feel you belong? (Please circle)
878
879 White Black / African / Caribbean / Black 
880 British
881 - English / Welsh / Scottish / Northern Irish - African 
882 / British Irish - Caribbean 
883 - Gypsy or Irish Traveller - Other (please 
884 specify)……………………………..
885 - Other (please specify) ……………………………..
886
887 Mixed/Multiple ethnic groups Other ethnic group
888 - White and Black Caribbean - Arab 
889 - White and Black African - Other (please 
890 specify)…………………………
891 - White and Asian 
892 - Other (please specify) ……………………………..
36
893
894 Asian / Asian British I’d prefer not to say
895 - Indian 
896 - Pakistani 
897 - Bangladeshi 
898 - Chinese 
899 - Other (please specify) …………………………
900
901 (20) Have you had any children before?
902 ☐ Yes.
903 If yes, how many?....................................................................
904 What are their ages?
905 Child 1: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐
906 Child 2: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐
907 Child 3: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐ 
908 ☐ No
909




914 2) Questions for healthcare professionals analysed in this study
915
916 (1) Before taking part in this survey, how familiar were you with Respiratory Syncytial Virus 
917 (sometimes shortened to RSV)?
918 ☐ I have never heard of it
919 ☐ I have heard of it, but don’t really know what it is
920 ☐ I know some facts about what it is 
921 ☐ I have a good understanding about RSV infection and its implications 
922
923 (2) What experience do you have of RSV?
924 ☐ I have no experience of it
925 ☐ I know someone who has experience of it
926 ☐ I have direct experience of it 
927
928 (3) How common do you think RSV infection is in young children?
929 ☐ Not at all common
930 ☐ Slightly common
931 ☐ Somewhat common
932 ☐ Moderately common
933 ☐ Extremely common
934      
935 (4) How serious do you think RSV infection is for young children?
936 ☐ Not at all serious
937 ☐ Slightly serious
938 ☐ Somewhat serious
939 ☐ Moderately serious
940 ☐ Extremely serious
941      
942 (5) Before taking part in this survey, how familiar were you with bronchiolitis in young children?
943 ☐ I have never heard of it
944 ☐ I have heard of it but don’t know what it is
945 ☐ I know some facts about it
946 ☐ I know what it is and know someone who has experience of it
947 ☐ I know what it is and have direct experience of it 
948
949 (6) How common do you think bronchiolitis is in young children?
950 ☐ Not at all common
951 ☐ Slightly common
37
952 ☐ Somewhat common
953 ☐ Moderately common
954 ☐ Extremely common
955
956  (7) How serious do you think bronchiolitis is for young children?
957 ☐ Not at all serious
958 ☐ Slightly serious
959 ☐ Somewhat serious
960 ☐ Moderately serious
961 ☐ Extremely serious
962
963 (8) Would you be potentially willing to support a randomised controlled trial of RSV vaccine in 
964 pregnancy to determine its safety and how well it prevents infection in children, by signposting 
965 the study to women? 
966 Your response to this question will not affect whether or not you receive further information about such 
967 studies
968
969 ☐ Extremely unlikely
970 ☐ Unlikely
971 ☐ Neutral/not sure
972 ☐ Likely
973 ☐ Extremely likely
974
975 (9) Would you be willing to support the administration of this vaccine if it was routinely 




980 ☐ Probably not
981 ☐ Definitely not
982
983 (10) What factors would influence your decision regarding whether or not you would be willing 
984 to support involvement in a RSV vaccine research study before it is licensed?
985
986 Please rank the top 3 factors:  (1= factor that would most influence you)
987
988 ☐ The number of pregnant women who had previously received the vaccine in research studies
989 ☐ How common RSV is in children
990 ☐ Seriousness of RSV infection in young children 
991 ☐ How effective the vaccine is in preventing RSV infection
992 ☐ How effective the vaccine is in preventing severe RSV disease
993 ☐ Risk of side effects for the mother
994 ☐ Risk of side effects for developing baby
995 ☐ Other (please specify): 
996 …………………………………………………………………………………………………….
997
998 (11) How many pregnant women would the vaccine have to be safely tested on in a research 
999 study for you to consider supporting such a trial?
1000 ☐ None
1001 ☐ Over 10
1002 ☐ Over 100
1003 ☐ Over 500
1004 ☐ Over 1000
1005 ☐ Over 5000
1006 ☐ Over 10,000
1007 ☐ I would not support such a trial
1008




1012 ☐ Other (please state) 
1013 …………………………………………………………………………………………
1014
1015 (13) How long have you worked in maternity care?
1016 ☐ Under 2 years
1017 ☐ 2-5 years
1018 ☐ 6-10 years 
1019 ☐ 11-15 years
1020 ☐ 16-20 years 
1021 ☐ 21+ years 
1022
1023 (14) What is your grade?
1024 1. Midwifery/nursing staff
1025 Band 4 ☐       Band 5 ☐       Band 6 ☐         Band 7 ☐        Band 8 ☐        Band 9 ☐
1026 2. Obstetricians
1027 ST 1-3 (or equivalent) ☐     ST 4-6 (or equivalent) ☐      ST 7-8 (or equivalent) ☐     Consultant 
1028 ☐
1029
1030 (15) Have you had any children before?
1031 ☐ Yes.
1032 If yes, how many?....................................................................
1033 What are their ages?
1034 Child 1: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐
1035 Child 2: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐
1036 Child 3: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐ 
1037 Child 4: Less than 1 ☐   1-5 ☐    6-10 ☐    11-16 ☐    17+ ☐   
1038 ☐ No
1039
1040 (16) To what ethnic group do you feel you belong? (Please circle)
1041
1042 White Black / African / Caribbean / Black 
1043 British
1044 - English / Welsh / Scottish / Northern Irish - African 
1045 / British Irish - Caribbean 
1046 - Gypsy or Irish Traveller - Other (please 
1047 specify)……………………………..
1048 - Other (please specify) ……………………………..
1049
1050 Mixed/Multiple ethnic groups Other ethnic group
1051 - White and Black Caribbean - Arab 
1052 - White and Black African - Other (please 
1053 specify)…………………………
1054 - White and Asian 
1055 - Other (please specify) ……………………………..
1056
1057 Asian / Asian British I’d prefer not to say
1058 - Indian 
1059 - Pakistani 
1060 - Bangladeshi 
1061 - Chinese 
1062 - Other (please specify) …………………………
1063
1064 (17) Optional: Do you have any comments or concerns about vaccination or vaccine research 










1074 3) Free-text comments from pregnant women and healthcare 
1075 professionals
1076
1077 Response to the question: Do you have any comments or concerns about vaccination or vaccine 




1082 1. I think vaccine trials are very risky even though very important so every available 
1083 information should be made available to the participant before commencing including 
1084 all known possible side effects
1085
1086 2. Many vaccines contain unsafe levels of mercury in some cases some are produced 
1087 on human tissue (DNA) and contain various other toxins. I believe a baby is born with 
1088 a perfect immune system which takes up to 3 years to fully develop and that it's not 
1089 healthy injecting a perfectly healthy child with chemicals and toxins (mercury)
1090
1091 3. I am glad to hear that the NICE guidelines will be reviewed and that possibly new 
1092 vaccines will be introduced
1093
1094 4. I am taking part in a RSV vaccine trial
1095
1096 5. I'm very keen for my baby to have as many vaccines as possible & fully support such 
1097 research
1098
1099 6. I would want the vaccine fully tested and approved before I would have it
1100
1101 7. Our daughter suffered from bronchiolitis at age 2 weeks old so as long as the vaccine 
1102 was safe we would definitely have it to prevent this baby suffering like our daughter 
1103 did
1104
1105 8. I would consider vaccination if I was having a normal singleton pregnancy
1106
1107 9. I'm a bit of a unique case because I've had an adverse reaction to a vaccine in the 
1108 past and wouldn't risk it in pregnancy unless I had to
1109
1110 10. Child died at 20 months. RSV sounds very like what my son had when he died
1111
1112 11. No concerns. I am very pro vaccinations both for myself during pregnancy and for my 
1113 children 
1114
1115 12. I am having a slightly bumpy pregnancy and this is one of the reasons I would be 
1116 reluctant to take part in a research study which could increase the risks for the 
1117 pregnancy complications. If I was a low-risk person I would be more willing to take 
1118 part. Likewise, if this wasn't my first baby I might be more willing
1119
1120 13. Information about the potential side effects of the trial vaccinations would have been 
1121 helpful for me to make more informed decisions
1122
1123 14. I've not heard of RSV before sounds concerning and something I would have liked to 
1124 have been told about earlier in my pregnancy
1125
1126 15. I've heard of many children developing chest infections as young babies and anything 
1127 to avoid this I feel should be actively encouraged
40
1128
1129 16. I would like the opportunity to ask more questions and have more information before 
1130 agreeing to vaccination 
1131
1132 17. I would only have medication in pregnancy that has been approved by the BMA. 
1133 Diabetics have a lot of complications anyway
1134
1135 18. No - thank you for all the amazing work/research you do
1136
1137 19. I believe the stage of drug trial to be more pertinent to the decision-making process 
1138 than the number of vaccinations received.
1139
1140 20. My concern in taking part in a research study is the unknown side effects to my baby 
1141 and whether the potential side effects would cause more harm than the virus itself. 
1142 Whilst I appreciate research needs to be done and the vaccine will have been 
1143 thoroughly tested on other test groups testing pregnant women/babies is still a 
1144 concern for me 
1145
1146 21. Not really aware enough of the issue to comment on some of the questions
1147
1148 22. In my experience, the flu vaccine has made me ill. I would not feel comfortable having 
1149 a trial vaccine as a first-time mother
1150
1151 Maternity healthcare professionals
1152
1153 1. I would want to see safety data in non-pregnant participants concerning side effects 
1154 and efficacy before I supported vaccine studies on pregnant women. I understand 
1155 that effectiveness in preventing baby bronchiolitis could not be assessed using non-
1156 pregnant subjects but would reassure health workers that we aren't supporting an 
1157 action that could cause harm.
1158
1159 2. I would worry about safety /side effects to mum and baby if not tested before being 
1160 given to pregnant women
1161
1162 3. Knowledge to midwives about RSV is very limited without having first-hand 
1163 experience of it or working alongside paediatric teams. It’s not widely taught in 
1164 training perhaps because our care for infants doesn't go much beyond 10-28 days 
1165 postnatally 
1166
1167 4. My son needed ECMO because of this infection but he was too unstable to transfer to 
1168 Gt O S we very nearly lost him at 12 days old. He caught it from his sister who was 2 
1169 and poorly when he was born. This serious infection wiped the first 2 months of a 
1170 normal newborn period for us. He did get asthma as a child and took months to catch 
1171 up. 
1172
1173 5. Side effects - baby especially.
1174
1175 6. I'm not convinced that RS virus needs vaccination. Depends on the severity of 
1176 chance of later disease in the child. I think we build up immunity ourselves and 
1177 therefore the number needed to treat is probably high to prevent severe RS virus 
1178 infection in children.
1179
1180 7. I would want some evidence that the vaccine is safe.
1181
1182 8. My children were born at 27/40 and 32/40 week’s gestation. For our 27/40 week-old 
1183 baby it was very serious.
1184
1185 9. Potential risks to unborn and ability to be honest with mother about risks v benefits.
1186
1187 10. Risk to unborn.
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1188
1189 11. Can’t really answer question of how many women vaccines would have to be safely 
1190 tested on as I don't know what the predicted rate of adverse reactions/side effects. As 
1191 long as sufficiently powered I would be happy. No concerns as long as properly 
1192 conducted. Vaccination research environment is heavily regulated so very confident.
1193
1194 12. That the vaccine is safe for the mother and unborn child. This has to be paramount 
1195 and is of high concern with the majority of the public.
1196
1197 13. When testing for side effects -there should be follow-up of at least 5 years on the 
1198 child whose mother received the vaccine. We are woefully short on long-term effects 
1199 and in order to fully discuss (and understand) the effects of vaccinations in pregnancy 
1200 these time-frames should be mandatory. Lack of long-term data does not reassure 
1201 me that we should be vaccinating in pregnancy.
1202
1203 14. Effect on the baby that are so far unknown. Another vaccine could it be combined 
1204 with present vaccines?
1205
1206 15. I would worry about a trial re the long term unknown effects on the health of children 
1207 whose mothers received the vaccine whilst they were in utero.
1208
1209 16. Yes, the potential risks to mother and unborn baby
1210
